Atlas Venture Fund X, Lp files Form 144 to sell 480,992 KYMR shares worth $48.0MAtlas Venture Fund X, Lp 提交 Form 144：拟减持 KYMERA THERAPEUTICS, INC. (KYMR) 480,992 股，约 $48.0M
Planned Sale Disclosure Details
On June 25, 2026, institutional shareholder Atlas Venture Fund X, LP filed a Form 144 planned sale disclosure with the U.S. Securities and Exchange Commission (SEC) for KYMR (KYMERA THERAPEUTICS, INC.), proposing to sell 480,992 common shares of the company, with an aggregate market value of approximately $48,036,671. Both the planned execution date and filing date for this proposed sale are June 25, 2026, and the full disclosure is available via the SEC filing link:
Core Significance of Form 144
Form 144 is a required SEC notice for affiliated parties or large shareholders intending to sell publicly traded securities. This document only discloses potential future share supply from sell-side plans, and does not confirm that shares have already been sold. Unlike Form 4, which reports completed insider transactions, Form 144 only records intended sales, and shareholders may adjust or cancel the proposed plan at any time.
Institutional and Analyst Context
Public institutional holding data shows that as of December 31, 2025, KYMR had 262 institutional holders, an increase of 45 from the prior quarter, with total institutional holdings valued at $7.5 billion, representing 102.9% of the company’s outstanding float. Of these holders, 67 were new positions, 166 increased their existing stakes, 64 reduced their positions, and 23 fully closed their holdings. Additionally, as of June 1, 2026, analyst coverage for KYMR included 5 strong buy ratings, 18 buy ratings, and 1 hold rating, with no significant changes to the rating distribution over the prior two months.
Signal Limitations and Next Steps
This Form 144 disclosure only reflects a single shareholder’s intended sale, and does not confirm that the proposed shares will actually be sold. The planned sale may stem from the shareholder’s liquidity needs or portfolio diversification efforts, and does not directly signal a negative view of the company’s fundamentals. This signal does not constitute investment advice, nor does it predict the specific impact of this potential sell-side activity on KYMR’s stock price. Market participants should monitor future SEC filings, including Form 4 submissions, to confirm whether the proposed sale is executed, as well as any additional large-shareholder sale disclosures.
拟售股份披露详情
2026年6月25日，机构股东Atlas Venture Fund X, LP向美国SEC提交了针对KYMR（KYMERA THERAPEUTICS, INC.）的Form 144拟售股份披露文件，计划出售480,992股公司普通股，总市值约4803.67万美元。本次拟售的计划执行日期与文件提交日期均为2026年6月25日，完整披露可通过SEC档案链接
Form 144披露的核心意义
Form 144是美国SEC要求的关联方或大额股东拟出售公开交易证券的预先通知文件，该文件仅披露潜在的未来卖盘供应，并不代表股份已完成实际出售。与记录已完成内幕交易的Form 4不同，Form 144仅记录出售意向，股东可随时调整或取消拟售计划。
机构持仓与分析师评级背景
公开机构持仓数据显示，截至2025年12月31日，KYMR共有262家机构投资者持仓，较上一季度增加45家，总机构持仓市值达75亿美元，占公司流通股比例达102.9%。其中67家为新进入的机构持仓，166家增持现有头寸，64家减持，23家完全清仓。此外，截至2026年6月1日，覆盖该公司的分析师评级分布为5次强力买入、18次买入、1次持有，近两个月评级未发生显著变化。
信号局限性与后续关注
本次Form 144披露仅反映单一股东的拟售意向，无法证明该出售行为一定会执行。该拟售计划可能仅出于股东的资产多元化或流动性需求，并不直接反映对公司基本面的负面判断。本信号不构成任何投资建议，也无法预测该潜在卖盘对公司股价的具体影响。市场参与者可后续关注SEC后续备案文件（如Form 4提交情况）以确认拟售是否实际执行，同时留意其他大额股东的出售披露。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。